Dermatologic Surgery

2025

Autologous Fat Transplantation: Treating Chronic Fibrosis Caused by Doxorubicin Extravasation

Ercan Çalişkan; Sema Nur Doğan; Akın Tuna; Ayşenur Botsali

Summary

Study on the use of autologous fat transplantation to treat chronic fibrosis caused by doxorubicin (chemotherapy) extravasation. Demonstrates the potential of fat grafting in tissue regeneration and fibrosis repair following iatrogenic chemical injury.

Summary prepared by the Reoneer scientific team. For methods, results and limitations, please refer to the original publication.

Citation details

Journal / source

Dermatologic Surgery

Published

June 2025

Volume

51

Issue

6

Pages

651-653

DOI

10.1097/dss.0000000000004563

PMID

39868696

Document type

Journal article

Study design

Sample size (n)

Language

English

Licence

Keep exploring

More publications

New

Key

Acta Orthopaedica Belgica

2026

Preclinical study comparing platelet-derived extracellular vesicle (exosome)-rich plasma with two commercial PRP preparations in a rabbit skeletal muscle injury model. A standardised partial injury was created in the…

Agir, Guler, Sarikas et al.

New

Key

Aesthetic Surgery Journal

2025

Retrospective study evaluating platelet-derived autologous exosome injections for female sexual dysfunction. Sixty patients were divided into four groups of 15 by injection site (clitoral glans, G-spot, periurethral…

Aglamis

New

Key

Archives of Physical Medicine and Rehabilitation

2025

Prospective RCT/review study evaluating the clinical efficacy of extracorporeal shock wave therapy (ESWT) combined with PRP and exercise for lateral epicondylitis (tennis elbow). Examines synergistic effect of these…

Akçin, Eyvaz, Dündar et al.

For Pioneers of Regenerative Medicine​

Subscribe to our email list now to be informed about all new publications and webinars.

Get notified about new articles

Subscription Form

WhatsApp Channel

Join our exclusive community on WhatsApp for the latest updates and special offers!

Telegram Channel

Follow the conversation and never miss an announcement: Subscribe to our Telegram channel today!